# US Plasma Fractionation Market

> US Plasma Fractionation Market Research Report By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By Application (Neurology, Hematology, General Medicine, Immunology), By End User (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies) and By Technology (Centrifugation, Chromatography, Precipitation, Filtration) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.5%
- **2024:** $ 8.5 Billion
- **2025:** $ 9.05 Billion
- **2035:** $ 17 Billion
- **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US), Hualan Biological Engineering (CN)These organizations are among the leading plasma manufacturers and blood fractionation companies operating within the US plasma fractionation ecosystem.

**Report ID:** MRFR/HC/13160-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** June 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-plasma-fractionation-market-14687

---

## Market Summary

## **US Plasma Fractionation Market Overview**

As per MRFR analysis, the US Plasma Fractionation Market Size was estimated at 4.77 (USD Billion) in 2024. The US Plasma Fractionation Market Industry is expected to grow from 5.1(USD Billion) in 2025 to 8.2 (USD Billion) by 2035. The US Plasma Fractionation Market CAGR (growth rate) is expected to be around 4.412% during the forecast period (2025 - 2035).

### **Key US Plasma Fractionation Market Trends Highlighted**

The US Plasma Fractionation Market is driven by several key factors that influence its growth and development. The increasing prevalence of chronic diseases and the rising demand for immunoglobulin therapies significantly shape the market landscape. The growing number of hemophilia patients and the need for clotting factor concentrates further contribute to the demand for plasma-derived products. The U.S. government supports this sector through regulatory frameworks and funding initiatives, promoting safe and efficient plasma collection and fractionation processes. As more healthcare providers recognize the benefits of plasma therapies, the market continues to gain traction.

There are also various opportunities to be explored within the US Plasma Fractionation Market. The advancement of technology in blood plasma processing and the development of new therapeutic applications offer potential avenues for expansion. Moreover, increasing awareness regarding rare diseases, which often require specific plasma-derived treatments, opens up pathways for innovative solutions. Collaborations between healthcare sectors, research institutions, and plasma collection centers could leverage shared expertise to improve treatment options. In recent times, trends such as the rise of specialty pharmacies and personalized medicine are gaining momentum.

These trends impact how plasma products are marketed and distributed, tailoring approaches to meet the needs of individual patients more effectively. The focus on patient-centered care encourages product developers to innovate and enhance existing therapies. The continuous rise in the number of plasma donation centers in the U.S. illustrates a commitment to improving access to these life-saving treatments, further reflecting the dynamic nature of the Plasma Fractionation Market in the region.

## 

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **US Plasma Fractionation Market Drivers**

### **Increasing Demand for Immunoglobulin Products**

The US Plasma Fractionation Market Industry is witnessing a significant increase in demand for immunoglobulin products, essential for treating various healthcare conditions, including immunodeficiencies and autoimmune disorders. The National Institutes of Health reported that primary immunodeficiency diseases affect approximately 1 in 1,200 individuals in the United States, which translates to around 250,000 cases. With the rise in awareness and diagnosis of these disorders, the demand for immunoglobulin has surged, leading to an expected market growth.

Key industry competitors, which include Grifols along with CSL Behring, have been increasing their production capabilities in response to market demand, which has, in turn, benefitted the growth of the US Plasma Fractionation Market.

### **Growing Number of Plasma Donation Centers**

The expansion of plasma donation centers across the United States has significantly facilitated the availability of raw plasma for fractionation. According to the American Association of Blood Banks, there were over 900 licensed plasma collection centers in the U.S. as of recent data. This is an increase of approximately 30% in the last decade, which enhances the supply chain for the US Plasma Fractionation Market Industry, allowing manufacturers to harness more plasma for essential therapies.

Organizations like Octapharma are investing in establishing more centers, ensuring a robust supply of plasma, thus enabling continued growth in the market.

### **Advancements in Plasma Processing Technologies**

Technological advancements in plasma processing are enhancing the efficiency and yield of plasma fractionation, driving growth in the US Plasma Fractionation Market Industry. Innovations such as improved separation techniques and the development of automated systems have increased the recovery rates of therapeutic proteins from plasma. According to the U.S. Food and Drug Administration, recent technology upgrades have led to a 25% increase in yield from the plasma fractionation process.

Companies like Takeda Pharmaceutical have actively adopted these technologies, strengthening their market position and contributing to overall industry growth in the United States.

### **Rising Incidence of Chronic Conditions Requiring Plasma-Derived Therapies**

The rise in chronic conditions such as hemophilia, hepatitis, and other blood-related disorders is significantly fueling the demand for plasma-derived therapies in the US Plasma Fractionation Market Industry. The Centers for Disease Control and Prevention (CDC) estimate that approximately 15,000 people in the U.S. are affected by hemophilia, a condition that requires regular infusions of clotting factor derived from plasma. With advancements in medical treatments and an increase in patient awareness, the utilization of plasma-derived products for managing these conditions is expected to grow.

This trend is being supported by major healthcare providers, which are emphasizing comprehensive care for chronic patients.

## **US Plasma Fractionation Market Segment Insights**

### **Plasma Fractionation Market Product Type Insights**

The US Plasma Fractionation Market, particularly in the Product Type segment, encompasses a diverse range of components that are crucial for therapeutic applications. Immunoglobulin is one of the most significant fractions, widely recognized for its role in treating various immune deficiencies and other related disorders. This segment holds a dominant position in the market due to its broad spectrum of clinical applications, including autoimmune diseases and infections, reflecting a growing demand among healthcare providers.

Albumin, another vital product derived from plasma, is essential for fluid management in patients, especially those undergoing surgery or suffering from liver diseases. Its versatility and importance in critical care settings have contributed to its substantial market presence.

Coagulation factors, which are essential in managing bleeding disorders such as hemophilia, present another critical aspect of the Plasma Fractionation Market. The increasing prevalence of these disorders has driven innovation and an expanding patient population in need of effective treatments, making this segment particularly significant for ongoing market growth. Additionally, protease inhibitors, though less widespread compared to Immunoglobulin and Albumin, play an essential role in addressing viral infections and inflammatory conditions.

Their incorporation into treatment protocols has been pivotal, highlighting evolving therapeutic strategies rooted in plasma-derived products. Overall, the segmentation of the US Plasma Fractionation Market sheds light on how various product types serve specific medical needs, promoting considerable advancements in patient care and treatment efficacy across the healthcare spectrum.

This market segment continues to evolve, harnessing technological innovations and increased awareness to drive growth opportunities while also adapting to regulatory landscapes and healthcare demands. As the healthcare infrastructure in the U.S. emphasizes improved treatment outcomes and specialized therapies, each product type within this market demonstrates its unique contributions and sustained relevance in shaping the future of plasma-derived therapeutics.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Plasma Fractionation Market Application Insights**

The US Plasma Fractionation Market is a vital component of the healthcare industry, particularly in the Application segment, which encompasses various disciplines such as Neurology, Hematology, General Medicine, and Immunology. Neurology remains a crucial area due to the increasing prevalence of neurological disorders, where plasma-derived therapeutics play a significant role in treatment protocols. In Hematology, products derived from plasma fractionation are essential for managing blood-related conditions, showcasing the importance of this segment in patient care.

General Medicine integrates diverse applications of plasma products, demonstrating their versatility and wide acceptance in clinical practices. [Immunology](../../../reports/immunology-market-30261) is also a key focus, as the demand for immunoglobulin therapies continues to rise, reflecting the increasing awareness and diagnosis of autoimmune diseases. The growth in these applications is fueled by advancing medical technology, increased funding for Research and Development, and a rising geriatric population, which highlights the necessity for innovative treatment solutions.

The ongoing development of new plasma-based therapies presents significant opportunities while navigating regulatory frameworks and supply chain challenges remains a key consideration within the industry landscape.

### **Plasma Fractionation Market End User Insights**

The 'End User' segment of the US Plasma Fractionation Market is diverse, comprising key entities such as Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals are central to plasma fractionation as they provide critical care services that depend on plasma-derived products for treating various medical conditions. Ambulatory Surgical Centers play a crucial role by enhancing patient access to specialized treatments involving plasma therapies, thereby streamlining service delivery. Blood Banks are indispensable, serving as collection, testing, and distribution hubs for plasma, with stringent regulations in place to ensure safety and efficacy in handling blood components.

Pharmaceutical Companies dominate the market by developing innovative therapies derived from plasma, thus driving advancements in treatment methodologies. The interplay of these users amid ongoing research and regulatory changes shapes the market landscape, with increasing demand for immunoglobulins and clotting factor concentrates underscoring their significance in healthcare. The ongoing improvements in processing technology and patient treatment protocols signal growth opportunities, while challenges related to supply chain management and regulatory compliance persist for these stakeholders.

### **Plasma Fractionation Market Technology Insights**

The Technology segment of the US Plasma Fractionation Market plays a critical role in the effective separation and purification of plasma components, which is essential for various medical applications. Within this segment, Centrifugation stands out due to its efficiency in separating plasma proteins based on density, making it a widely used technique in laboratories. Chromatography is also significant as it provides high-resolution separation, critical for the purification of specific proteins required in therapies, reflecting increasing demand for more refined therapeutic products.

Precipitation methods offer another avenue for isolating plasma proteins, leveraging changes in solubility, and are continuously evolving to enhance efficiency and yield in clinical settings. Finally, Filtration techniques are important for their ability to maintain sterility while selectively filtering plasma components, ensuring safe and effective usage in medical treatments. The continuous advancements in these technologies foster innovation within the US Plasma Fractionation Market, contributing to improved patient outcomes and addressing the growing need for therapeutics derived from human plasma.

The integration of automation and real-time monitoring systems is also poised to enhance operational efficiency and regulatory compliance in this dynamic landscape.

## **US Plasma Fractionation Market Key Players and Competitive Insights**

The US Plasma Fractionation Market is characterized by a dynamic competitive landscape where various players strive to enhance their portfolios and market positioning through innovation and expansion. As the global demand for plasma-derived medicinal products continues to grow, companies operating within this sector are focusing on advancing their technologies, improving operational efficiency, and expanding their capacity to meet healthcare needs.

This market is influenced by factors such as regulatory frameworks, technological advancements, and the increasing prevalence of chronic diseases that necessitate the use of plasma-derived therapeutics. In addition, strategic partnerships and collaborations play a pivotal role as organizations seek to leverage collective strengths to innovate and enhance their market reach.

Cerus Corporation stands out in the US Plasma Fractionation Market with its proprietary technologies that focus on pathogen reduction and blood safety. The company has established a credible presence through its innovative Intercept Blood System, which is designed to reduce the risk of transfusion-transmitted infections. With an emphasis on safety and efficacy, Cerus Corporation has garnered a strong reputation for its commitment to enhancing blood product quality.

The company’s advancements in pathogen reduction technologies, along with a robust regulatory approval history, position it favorably among healthcare providers looking for reliable solutions. Additionally, Cerus Corporation has strategically positioned itself to expand its market share by aligning with various blood centers, thereby increasing its accessibility and operational footprint within the United States.

Octapharma is another key player in the US Plasma Fractionation Market, known for its focus on producing high-quality human protein products derived from human plasma. The company emphasizes therapeutic areas, including hematology, immunotherapy, and intensive care, delivering a range of immunoglobulins, coagulation factors, and albumins that cater to diverse patient needs.

Octapharma’s strong market presence in the U.S. is underlined by its commitment to research and development, allowing it to introduce innovative therapies adapting to evolving healthcare demands. The company has also engaged in significant mergers and acquisitions, fortifying its position within the market and expanding its product offerings. By collaborating with health organizations and maintaining a focus on quality assurance, Octapharma enhances its operational strengths, ensuring that it remains a trusted name in the plasma-derived medicinal product space.

### **Key Companies in the US Plasma Fractionation Market Include**

## **US Plasma Fractionation Market Industry Developments**

Recent developments in the US Plasma Fractionation Market have highlighted a surge in interest and activity among key players. For instance, in August 2023, Cerus Corporation announced advancements in its INTERCEPT Blood System technology, aiming to enhance safety protocols in plasma transfusions.

In July 2023, Grifols expanded its production capacity in North Carolina to meet the rising demand for immunoglobulin therapies. Furthermore, Baxter International revealed its plans to increase operational efficiencies by automating certain plasma processing procedures earlier in September 2023.

The market is also witnessing significant growth in valuation, driven by an increasing incidence of chronic diseases and an expanded patient population requiring plasma-derived therapies. Among recent strategic activities, in June 2023, Takeda Pharmaceutical finalized the acquisition of a biologics facility from Shire, enhancing its capabilities in the plasma sector.

Moreover, CSL Behring launched new products targeting rare bleeding disorders, which contributed to a positive market outlook. The American Red Cross continues to play a vital role in plasma collection efforts, ensuring a steady supply for therapeutic needs. These activities indicate a robust and evolving market landscape in the U.S. Plasma Fractionation sector.

## **Plasma Fractionation Market Segmentation Insights**

### **Plasma Fractionation Market Product Type Outlook**

### **Plasma Fractionation Market Application Outlook**

### **Plasma Fractionation Market End User Outlook**

### **Plasma Fractionation Market Technology Outlook**

## Market Drivers

### Rising Demand for Immunoglobulins

The plasma fractionation market is experiencing a notable increase in demand for immunoglobulins, which are critical for treating various immune deficiencies and autoimmune disorders. This surge is driven by a growing awareness of the therapeutic benefits of immunoglobulins, leading to a projected market growth of approximately 8% annually. The increasing prevalence of chronic diseases and the aging population in the US further contribute to this demand. As healthcare providers seek effective treatments, the plasma fractionation market is positioned to expand significantly, with immunoglobulin therapies becoming a cornerstone of patient care. This trend indicates a robust future for the industry, as manufacturers strive to enhance production capabilities to meet the rising needs of healthcare systems.

### Growing Focus on Personalized Medicine

the plasma fractionation market aligns with the growing focus on personalized medicine, which emphasizes tailored treatment approaches for individual patients. This trend is particularly relevant as healthcare systems strive to improve patient outcomes through customized therapies. Plasma-derived products are being developed to meet specific patient needs, enhancing their efficacy and safety profiles. The market is likely to see a shift towards more personalized treatment options, with an anticipated growth rate of 9% in the coming years. As healthcare providers increasingly adopt personalized medicine strategies, the plasma fractionation market is expected to play a crucial role in delivering targeted therapies that address the unique characteristics of patients.

### Advancements in Fractionation Technologies

Innovations in fractionation technologies are transforming the plasma fractionation market, enabling more efficient and cost-effective production processes. Techniques such as chromatography and membrane filtration are being refined, leading to higher yields and purities of plasma-derived products. These advancements not only enhance the quality of therapeutic proteins but also reduce production costs, making treatments more accessible. The market is projected to grow as these technologies become more widely adopted, with an estimated increase of 10% in efficiency reported by leading manufacturers. As a result, the plasma fractionation market is expected to see a surge in investment aimed at further technological enhancements, ensuring a competitive edge in the healthcare landscape.

### Increasing Investment in Biopharmaceuticals

The plasma fractionation market is benefiting from a significant rise in investment in biopharmaceuticals, driven by the growing recognition of the value of plasma-derived therapies. In the US, biopharmaceutical investments have surged, with funding reaching over $50 billion in recent years. This influx of capital is facilitating research and development efforts, leading to the introduction of novel therapies and improved production methods. As biopharmaceutical companies expand their portfolios to include plasma-derived products, the plasma fractionation market is poised for substantial growth. This trend suggests a promising future for the industry, as new therapies emerge to address unmet medical needs and enhance patient outcomes.

### Expanding Applications of Plasma-Derived Products

the plasma fractionation market is expanding in the applications of plasma-derived products, which are increasingly utilized in various therapeutic areas. Beyond traditional uses in [immunology](https://www.marketresearchfuture.com/reports/immunology-market-30261), these products are now being explored for their potential in treating neurological disorders, trauma, and surgical procedures. This diversification is likely to drive market growth, as healthcare providers recognize the versatility of plasma-derived therapies. The market is expected to grow at a rate of approximately 7% annually, reflecting the increasing adoption of these products across different medical fields. As research continues to unveil new applications, the plasma fractionation market is set to evolve, offering innovative solutions to complex health challenges.

## Future Outlook

the plasma fractionation market is expected to grow at a 6.5% CAGR from 2024 to 2035, driven by increasing demand for immunoglobulins and advancements in fractionation technologies.

**New opportunities:**

- Expansion of contract manufacturing services for biopharmaceutical companies. Development of innovative plasma-derived therapies targeting rare diseases. Investment in automated plasma collection and processing technologies.

By 2035, the plasma fractionation market is expected to achieve robust growth and enhanced competitive positioning.

## Segment Insights

### By Application: Hematology (Largest) vs. Neurology (Fastest-Growing)

In the US plasma fractionation market, Hematology holds the largest share, primarily due to the increasing prevalence of blood disorders and the growing demand for immunoglobulin therapies. In contrast, Neurology is rapidly gaining traction, fueled by advancements in neurotherapeutics and increased investment in neurological research. Both segments are crucial for the overall growth of the market, but their dynamics differ significantly, with Hematology currently leading the charge. As the US plasma fractionation market evolves, Neurology is projected to grow at an impressive rate, driven by innovation in treatments for conditions such as multiple sclerosis and Alzheimer's disease. Factors such as an aging population and heightened awareness of neurological disorders contribute to this growth. Hematology, while still the dominant segment, must adapt to changing demands and new therapeutic developments to maintain its leading position.

Hematology: Dominant vs. Neurology: Emerging

Hematology is characterized by its established presence in the US plasma fractionation market, focusing on developing therapies for blood-related disorders, including hemophilia and thrombocytopenia. This segment benefits from well-recognized products and strong relationships with healthcare providers. On the other hand, Neurology represents an emerging segment, showcasing robust growth potential due to increasing neurological disease prevalence and advancements in treatment protocols. Neurology's innovations are attracting substantial research funding, setting the stage for competitive developments in novel therapies. As a result, these segments highlight a significant contrast, with Hematology's dominance balanced by Neurology's vibrant growth trajectory.

### By Product Type: Immunoglobulin (Largest) vs. Coagulation Factors (Fastest-Growing)

In the US plasma fractionation market, the product type segment showcases varying shares among its key values. Immunoglobulin dominates the landscape, held by substantial demand due to its therapeutic applications in various medical conditions. Albumin follows, catering to critical care treatments, while Coagulation Factors and Protease Inhibitors represent vital components in specialty therapies, albeit with smaller market shares. Growth trends within this segment reveal a robust expansion, particularly for Coagulation Factors, which are experiencing increasing prevalence in hemophilia treatment. Factors driving this growth include rising awareness of bleeding disorders and advancements in therapeutic interventions. Additionally, expanding indications for Immunoglobulin usage across different health conditions are bolstering the demand, confirming its established dominance in the market.

Immunoglobulin: Dominant vs. Coagulation Factors: Emerging

Immunoglobulin is recognized as the dominant product type in the US plasma fractionation market, known for its extensive use in treating immune deficiencies and autoimmune disorders. Its reliable efficacy and established safety profile contribute to sustained demand among healthcare providers. In contrast, Coagulation Factors, while currently an emerging segment, are rapidly gaining traction due to innovative therapies and increasing prevalence of genetic bleeding disorders. As advancements in biotechnology enhance the availability of these factors, their market share is expected to grow, appealing to more healthcare scenarios where bleeding control is essential.

### By End User: Hospitals (Largest) vs. Blood Banks (Fastest-Growing)

In the US plasma fractionation market, hospitals hold the largest market share, primarily due to their extensive utilization of plasma-derived therapies for various medical conditions. Following closely are blood banks, which are experiencing significant growth driven by the increasing demand for blood products and advancements in plasma collection technology. Ambulatory surgical centers and pharmaceutical companies also contribute to the market but represent a smaller share relative to hospitals and blood banks. The growth trends in this segment are largely influenced by the rising prevalence of chronic diseases and the growing emphasis on transfusion medicine. Hospitals continue to expand their services, while blood banks are innovating their operational efficiency and service offerings. As the healthcare landscape evolves, ambulatory surgical centers are also positioning themselves to capitalize on this trend by incorporating plasma therapies into their treatment options.

Hospitals (Dominant) vs. Blood Banks (Emerging)

Hospitals in the US plasma fractionation market are recognized as the dominant players due to their comprehensive healthcare services and the critical role they play in patient care, offering a range of treatments involving plasma-derived products. Their robust infrastructure and trained medical professionals enable them to implement [advanced](https://www.marketresearchfuture.com/reports/advanced-glycation-end-products-market-26113) plasma collection and processing methods effectively. In contrast, blood banks are emerging as vital entities, characterized by their specialized focus on plasma collection and distribution. With an increasing demand for donated plasma and innovative approaches to donor recruitment and retention, blood banks are enhancing their operational capabilities. This shift positions them to meet the evolving needs of healthcare providers, thereby making them a promising segment in the market.

### By Technology: Centrifugation (Largest) vs. Chromatography (Fastest-Growing)

In the US plasma fractionation market, the technology segment is primarily dominated by Centrifugation dominates due to its reliability in large-scale processing, while chromatography is gaining traction as plasma manufacturers focus on higher purity plasma-derived products. These advancements highlight evolving preferences among blood fractionation companies toward specialized separation techniques. Chromatography is gaining traction, gradually increasing its market share as advancements and specific applications expand. Precipitation and filtration, while essential, remain smaller segments compared to the leading two, reflecting the competitive landscape of the market. Centrifugation's leading position is driven by its effectiveness in large-scale processing, whereas chromatography is on a rapid growth trajectory, fueled by technological innovations and growing demand for purity in plasma-derived products. Factors such as increased research in therapeutic applications and a rise in plasma collection are propelling these segments forward, indicating a dynamic shift in preferences toward more specialized separation techniques that cater to specific clinical needs.

Technology: Centrifugation (Dominant) vs. Chromatography (Emerging)

Centrifugation is the dominant technology in the US plasma fractionation market, celebrated for its high throughput and efficiency in separating liquid components based on density. This method is widely adopted across various applications, including the production of immunoglobulins and clotting factors. Conversely, chromatography stands out as an emerging technology, noted for its precision and ability to achieve high purity levels in plasma derived products. As biopharmaceutical companies enhance their focus on developing complex therapies, the demand for chromatography is expected to grow significantly, allowing for the tailoring of treatment based on patient-specific needs. The evolution of these technologies indicates a trend towards increasingly sophisticated methods of plasma fractionation.

## Competitive Benchmarking

The plasma fractionation market is characterized by a dynamic competitive landscape, driven by increasing demand for immunoglobulins and clotting factors, alongside advancements in technology. Key players such as Grifols (Spain), CSL Behring (Australia), and Takeda Pharmaceutical Company (Japan) are at the forefront, each adopting distinct strategies to enhance their market positioning. Grifols (Spain) focuses on innovation through research and development, particularly in the area of rare diseases, while CSL Behring (Australia) emphasizes global expansion and strategic partnerships to bolster its product offerings. Takeda Pharmaceutical Company (Japan) is actively pursuing mergers and acquisitions to diversify its portfolio, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly shaped by innovation and strategic collaborations. In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several key players exerting influence over specific segments. This fragmentation allows for niche players to thrive, while larger companies leverage their scale to optimize operations and expand their reach. The collective influence of these key players fosters a competitive atmosphere where agility and responsiveness to market demands are paramount.
In October Grifols (Spain) announced a partnership with a leading biotechnology firm to develop next-generation therapies for immunodeficiencies. This collaboration is strategically significant as it not only enhances Grifols' R&D capabilities but also positions the company to capture a larger share of the growing market for specialized therapies. Such partnerships are indicative of a broader trend towards collaborative innovation in the sector.
In September CSL Behring (Australia) launched a new product line aimed at treating hemophilia, which underscores its commitment to addressing unmet medical needs. This strategic move is likely to strengthen CSL Behring's market presence and enhance its reputation as a leader in hemophilia treatment. The introduction of innovative products is essential for maintaining competitive advantage in a market that increasingly values differentiation.
In August Takeda Pharmaceutical Company (Japan) completed the acquisition of a smaller plasma-derived therapies company, which is expected to expand its product portfolio and enhance its operational capabilities. This acquisition reflects a strategic focus on growth through consolidation, allowing Takeda to leverage synergies and improve its market position. Such actions are indicative of a trend where larger firms seek to enhance their competitive edge through strategic acquisitions.
As of November current competitive trends in the plasma fractionation market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in operations. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition towards a focus on technological advancements, innovation, and supply chain reliability. This transition suggests that companies will need to invest in R&D and forge strategic partnerships to remain competitive in an ever-evolving market.

## Recent News & Developments

Recent developments in the US Plasma Fractionation Market reflect rising activity among leading **plasma manufacturers**. Capacity expansions, automation initiatives, and strategic acquisitions by major **blood fractionation companies** such as Grifols, CSL Behring, and Takeda Pharmaceutical continue to reshape the **blood plasma market** landscape. For instance, in August 2023, Cerus Corporation announced advancements in its INTERCEPT Blood System technology, aiming to enhance safety protocols in plasma transfusions.

In July 2023, Grifols expanded its production capacity in North Carolina to meet the rising demand for immunoglobulin therapies. Furthermore, Baxter International revealed its plans to increase operational efficiencies by automating certain plasma processing procedures earlier in September 2023.

The market is also witnessing significant growth in valuation, driven by an increasing incidence of chronic diseases and an expanded patient population requiring plasma-derived therapies. Among recent strategic activities, in June 2023, Takeda Pharmaceutical finalized the acquisition of a biologics facility from Shire, enhancing its capabilities in the plasma sector.

Moreover, CSL Behring launched new products targeting rare bleeding disorders, which contributed to a positive market outlook. The American Red Cross continues to play a vital role in plasma collection efforts, ensuring a steady supply for therapeutic needs. These activities indicate a robust and evolving market landscape in the U.S. Plasma Fractionation sector.

## Report Scope

| MARKET SIZE 2024 | 8.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.05(USD Billion) |
| MARKET SIZE 2035 | 17.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US), Hualan Biological Engineering (CN) |
| Segments Covered | Application, Product Type, End User, Technology |
| Key Market Opportunities | Advancements in purification technologies enhance efficiency in the plasma fractionation market. |
| Key Market Dynamics | Rising demand for immunoglobulins drives innovation and competition in the plasma fractionation market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US plasma fractionation market as of 2024?**
A: The US plasma fractionation market was valued at $8.5 Billion in 2024.

**Q: What is the projected market valuation for the US plasma fractionation market in 2035?**
A: The market is projected to reach $17.0 Billion by 2035.

**Q: What is the expected CAGR for the US plasma fractionation market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during 2025 - 2035 is 6.5%.

**Q: Which application segments are expected to drive growth in the US plasma fractionation market?**
A: The application segments include Neurology, Hematology, General Medicine, and Immunology, with valuations ranging from $1.5 to $5.0 Billion.

**Q: What are the key product types in the US plasma fractionation market?**
A: Key product types include Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors, with valuations from $0.6 to $6.8 Billion.

**Q: Who are the leading companies in the US plasma fractionation market?**
A: Leading companies include Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma.

**Q: What end-user segments are contributing to the US plasma fractionation market?**
A: End-user segments include Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies, with valuations from $1.2 to $6.8 Billion.

**Q: What technologies are utilized in the US plasma fractionation market?**
A: Technologies include Centrifugation, Chromatography, Precipitation, and Filtration, with valuations ranging from $1.7 to $5.0 Billion.

**Q: How does the growth of the US plasma fractionation market compare to its valuation in 2024?**
A: The market is expected to grow from $8.5 Billion in 2024 to $17.0 Billion by 2035.

**Q: What factors might influence the growth of the US plasma fractionation market in the coming years?**
A: Factors influencing growth may include advancements in technology, increasing demand for plasma-derived therapies, and the expansion of healthcare facilities.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-plasma-fractionation-market-14687*